Biogen Inc. (BIIB)

Market Cap	18.47B
Revenue (ttm)	9.82B
Net Income (ttm)	1.48B
Shares Out	146.53M
EPS (ttm)	10.12
PE Ratio	12.46
Forward PE	7.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,099,656
Open	127.20
Previous Close	126.92
Day's Range	125.60 - 128.25
52-Week Range	110.04 - 238.00
Beta	0.15
Analysts	Buy
Price Target	188.17 (+49.25%)
Earnings Date	Jul 31, 2025

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Sep 16, 1991
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: BIIB
• Website: https://www.biogen.com

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Analyst Forecast

According to 27 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $188.17, which is an increase of 49.25% from the latest price.

Price Target

$188.17

(49.25% upside)

Analyst Consensus: Buy